Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GEMONIL (metharbital) is an oral barbiturate tablet indicated for seizure management and sedation. Metharbital is a long-acting central nervous system depressant that enhances GABAergic inhibition. The product is currently in pre-launch stage under sponsor AbbVie.
Pre-Launch
Pre-launch stage suggests emerging commercial infrastructure build-out with potential for cross-functional team expansion pending approval.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GEMONIL represents a pre-launch opportunity with AbbVie, offering early-career exposure to regulatory approval workflows, market entry strategy, and potential repositioning of a legacy therapeutic class. Roles will emphasize infrastructure build, payer strategy, and education given competitive headwinds in the AED market.
Regulatory Affairs ManagerBrand Manager
Worked on GEMONIL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.